Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Atossa Therapeutics, retaining the price target of $4.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Jason McCarthy has given his Buy rating due to a combination of factors surrounding Atossa Therapeutics’ recent advancements. Atossa has received Rare Pediatric Disease designation from the FDA for its drug endoxifen, aimed at treating Duchenne muscular dystrophy (DMD). This designation not only highlights the potential of endoxifen in addressing serious conditions affecting young patients but also makes it eligible for a Priority Review Voucher if approved, which could significantly enhance its market value.
Additionally, the DMD space is highly active and lucrative, with recent successes in similar therapies leading to substantial stock value increases. Atossa’s endoxifen, with its broad safety profile and oral delivery method, offers a promising alternative to existing treatments by potentially increasing utrophin, a protein that can substitute for dystrophin. This strategic expansion into DMD, alongside its ongoing focus on breast cancer, positions Atossa well for future growth, making it an attractive investment opportunity.
According to TipRanks, McCarthy is an analyst with an average return of -13.0% and a 34.12% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Plus Therapeutics, and Atossa Therapeutics.
In another report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $7.00 price target.